company background image
XMS logo

Xtant Medical Holdings DB:XMS Stock Report

Last Price

€0.37

Market Cap

€53.1m

7D

-5.1%

1Y

-69.4%

Updated

26 Nov, 2024

Data

Company Financials +

Xtant Medical Holdings, Inc.

DB:XMS Stock Report

Market Cap: €53.1m

Xtant Medical Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xtant Medical Holdings
Historical stock prices
Current Share PriceUS$0.37
52 Week HighUS$1.28
52 Week LowUS$0.35
Beta0.38
11 Month Change-5.61%
3 Month Change-38.33%
1 Year Change-69.42%
33 Year Change-42.64%
5 Year Change-74.66%
Change since IPO-86.19%

Recent News & Updates

Recent updates

Shareholder Returns

XMSDE Medical EquipmentDE Market
7D-5.1%2.4%0.8%
1Y-69.4%-5.0%9.1%

Return vs Industry: XMS underperformed the German Medical Equipment industry which returned -5% over the past year.

Return vs Market: XMS underperformed the German Market which returned 9.1% over the past year.

Price Volatility

Is XMS's price volatile compared to industry and market?
XMS volatility
XMS Average Weekly Movement14.6%
Medical Equipment Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: XMS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: XMS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a211Sean Brownewww.xtantmedical.com

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.

Xtant Medical Holdings, Inc. Fundamentals Summary

How do Xtant Medical Holdings's earnings and revenue compare to its market cap?
XMS fundamental statistics
Market cap€53.06m
Earnings (TTM)-€16.79m
Revenue (TTM)€108.68m

0.5x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XMS income statement (TTM)
RevenueUS$113.86m
Cost of RevenueUS$44.53m
Gross ProfitUS$69.33m
Other ExpensesUS$86.92m
Earnings-US$17.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin60.89%
Net Profit Margin-15.45%
Debt/Equity Ratio76.1%

How did XMS perform over the long term?

See historical performance and comparison